Global Diagnostic Nuclear Medicines Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Diagnostic Nuclear Medicines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Diagnostic Nuclear Medicines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Diagnostic Nuclear Medicines market include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Diagnostic Nuclear Medicines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Diagnostic Nuclear Medicines, also provides the sales of main regions and countries. Of the upcoming market potential for Diagnostic Nuclear Medicines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diagnostic Nuclear Medicines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Diagnostic Nuclear Medicines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Diagnostic Nuclear Medicines sales, projected growth trends, production technology, application and end-user industry.
Diagnostic Nuclear Medicines Segment by Company
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
SIEMENS
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Diagnostic Nuclear Medicines Segment by Type
Tc-99m
F-18
Other
Diagnostic Nuclear Medicines Segment by Application
Oncology
Cardiology
Other
Diagnostic Nuclear Medicines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Diagnostic Nuclear Medicines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Diagnostic Nuclear Medicines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Diagnostic Nuclear Medicines significant trends, drivers, influence factors in global and regions.
6. To analyze Diagnostic Nuclear Medicines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Diagnostic Nuclear Medicines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diagnostic Nuclear Medicines industry.
Chapter 3: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Diagnostic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Diagnostic Nuclear Medicines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Diagnostic Nuclear Medicines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Diagnostic Nuclear Medicines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Diagnostic Nuclear Medicines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Diagnostic Nuclear Medicines market include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Diagnostic Nuclear Medicines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Diagnostic Nuclear Medicines, also provides the sales of main regions and countries. Of the upcoming market potential for Diagnostic Nuclear Medicines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diagnostic Nuclear Medicines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Diagnostic Nuclear Medicines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Diagnostic Nuclear Medicines sales, projected growth trends, production technology, application and end-user industry.
Diagnostic Nuclear Medicines Segment by Company
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
SIEMENS
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Diagnostic Nuclear Medicines Segment by Type
Tc-99m
F-18
Other
Diagnostic Nuclear Medicines Segment by Application
Oncology
Cardiology
Other
Diagnostic Nuclear Medicines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Diagnostic Nuclear Medicines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Diagnostic Nuclear Medicines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Diagnostic Nuclear Medicines significant trends, drivers, influence factors in global and regions.
6. To analyze Diagnostic Nuclear Medicines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Medicines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Diagnostic Nuclear Medicines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diagnostic Nuclear Medicines industry.
Chapter 3: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Diagnostic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Diagnostic Nuclear Medicines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
190 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Diagnostic Nuclear Medicines Sales Value (2020-2031)
- 1.2.2 Global Diagnostic Nuclear Medicines Sales Volume (2020-2031)
- 1.2.3 Global Diagnostic Nuclear Medicines Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Diagnostic Nuclear Medicines Market Dynamics
- 2.1 Diagnostic Nuclear Medicines Industry Trends
- 2.2 Diagnostic Nuclear Medicines Industry Drivers
- 2.3 Diagnostic Nuclear Medicines Industry Opportunities and Challenges
- 2.4 Diagnostic Nuclear Medicines Industry Restraints
- 3 Diagnostic Nuclear Medicines Market by Company
- 3.1 Global Diagnostic Nuclear Medicines Company Revenue Ranking in 2024
- 3.2 Global Diagnostic Nuclear Medicines Revenue by Company (2020-2025)
- 3.3 Global Diagnostic Nuclear Medicines Sales Volume by Company (2020-2025)
- 3.4 Global Diagnostic Nuclear Medicines Average Price by Company (2020-2025)
- 3.5 Global Diagnostic Nuclear Medicines Company Ranking (2023-2025)
- 3.6 Global Diagnostic Nuclear Medicines Company Manufacturing Base and Headquarters
- 3.7 Global Diagnostic Nuclear Medicines Company Product Type and Application
- 3.8 Global Diagnostic Nuclear Medicines Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Diagnostic Nuclear Medicines Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Diagnostic Nuclear Medicines Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Diagnostic Nuclear Medicines Market by Type
- 4.1 Diagnostic Nuclear Medicines Type Introduction
- 4.1.1 Tc-99m
- 4.1.2 F-18
- 4.1.3 Other
- 4.2 Global Diagnostic Nuclear Medicines Sales Volume by Type
- 4.2.1 Global Diagnostic Nuclear Medicines Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Diagnostic Nuclear Medicines Sales Volume by Type (2020-2031)
- 4.2.3 Global Diagnostic Nuclear Medicines Sales Volume Share by Type (2020-2031)
- 4.3 Global Diagnostic Nuclear Medicines Sales Value by Type
- 4.3.1 Global Diagnostic Nuclear Medicines Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Diagnostic Nuclear Medicines Sales Value by Type (2020-2031)
- 4.3.3 Global Diagnostic Nuclear Medicines Sales Value Share by Type (2020-2031)
- 5 Diagnostic Nuclear Medicines Market by Application
- 5.1 Diagnostic Nuclear Medicines Application Introduction
- 5.1.1 Oncology
- 5.1.2 Cardiology
- 5.1.3 Other
- 5.2 Global Diagnostic Nuclear Medicines Sales Volume by Application
- 5.2.1 Global Diagnostic Nuclear Medicines Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Diagnostic Nuclear Medicines Sales Volume by Application (2020-2031)
- 5.2.3 Global Diagnostic Nuclear Medicines Sales Volume Share by Application (2020-2031)
- 5.3 Global Diagnostic Nuclear Medicines Sales Value by Application
- 5.3.1 Global Diagnostic Nuclear Medicines Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Diagnostic Nuclear Medicines Sales Value by Application (2020-2031)
- 5.3.3 Global Diagnostic Nuclear Medicines Sales Value Share by Application (2020-2031)
- 6 Diagnostic Nuclear Medicines Regional Sales and Value Analysis
- 6.1 Global Diagnostic Nuclear Medicines Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Diagnostic Nuclear Medicines Sales by Region (2020-2031)
- 6.2.1 Global Diagnostic Nuclear Medicines Sales by Region: 2020-2025
- 6.2.2 Global Diagnostic Nuclear Medicines Sales by Region (2026-2031)
- 6.3 Global Diagnostic Nuclear Medicines Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Diagnostic Nuclear Medicines Sales Value by Region (2020-2031)
- 6.4.1 Global Diagnostic Nuclear Medicines Sales Value by Region: 2020-2025
- 6.4.2 Global Diagnostic Nuclear Medicines Sales Value by Region (2026-2031)
- 6.5 Global Diagnostic Nuclear Medicines Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Diagnostic Nuclear Medicines Sales Value (2020-2031)
- 6.6.2 North America Diagnostic Nuclear Medicines Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Diagnostic Nuclear Medicines Sales Value (2020-2031)
- 6.7.2 Europe Diagnostic Nuclear Medicines Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Diagnostic Nuclear Medicines Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Diagnostic Nuclear Medicines Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Diagnostic Nuclear Medicines Sales Value (2020-2031)
- 6.9.2 South America Diagnostic Nuclear Medicines Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Diagnostic Nuclear Medicines Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Diagnostic Nuclear Medicines Sales Value Share by Country, 2024 VS 2031
- 7 Diagnostic Nuclear Medicines Country-level Sales and Value Analysis
- 7.1 Global Diagnostic Nuclear Medicines Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Diagnostic Nuclear Medicines Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Diagnostic Nuclear Medicines Sales by Country (2020-2031)
- 7.3.1 Global Diagnostic Nuclear Medicines Sales by Country (2020-2025)
- 7.3.2 Global Diagnostic Nuclear Medicines Sales by Country (2026-2031)
- 7.4 Global Diagnostic Nuclear Medicines Sales Value by Country (2020-2031)
- 7.4.1 Global Diagnostic Nuclear Medicines Sales Value by Country (2020-2025)
- 7.4.2 Global Diagnostic Nuclear Medicines Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.9.2 France Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.16.2 China Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.19.2 India Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Diagnostic Nuclear Medicines Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Diagnostic Nuclear Medicines Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Diagnostic Nuclear Medicines Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Bracco Imaging
- 8.1.1 Bracco Imaging Comapny Information
- 8.1.2 Bracco Imaging Business Overview
- 8.1.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio
- 8.1.5 Bracco Imaging Recent Developments
- 8.2 Cardinal Health
- 8.2.1 Cardinal Health Comapny Information
- 8.2.2 Cardinal Health Business Overview
- 8.2.3 Cardinal Health Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Cardinal Health Diagnostic Nuclear Medicines Product Portfolio
- 8.2.5 Cardinal Health Recent Developments
- 8.3 Curium Pharma
- 8.3.1 Curium Pharma Comapny Information
- 8.3.2 Curium Pharma Business Overview
- 8.3.3 Curium Pharma Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Curium Pharma Diagnostic Nuclear Medicines Product Portfolio
- 8.3.5 Curium Pharma Recent Developments
- 8.4 GE Healthcare
- 8.4.1 GE Healthcare Comapny Information
- 8.4.2 GE Healthcare Business Overview
- 8.4.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.4.4 GE Healthcare Diagnostic Nuclear Medicines Product Portfolio
- 8.4.5 GE Healthcare Recent Developments
- 8.5 Jubilant Pharma
- 8.5.1 Jubilant Pharma Comapny Information
- 8.5.2 Jubilant Pharma Business Overview
- 8.5.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio
- 8.5.5 Jubilant Pharma Recent Developments
- 8.6 Lantheus
- 8.6.1 Lantheus Comapny Information
- 8.6.2 Lantheus Business Overview
- 8.6.3 Lantheus Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Lantheus Diagnostic Nuclear Medicines Product Portfolio
- 8.6.5 Lantheus Recent Developments
- 8.7 SIEMENS
- 8.7.1 SIEMENS Comapny Information
- 8.7.2 SIEMENS Business Overview
- 8.7.3 SIEMENS Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.7.4 SIEMENS Diagnostic Nuclear Medicines Product Portfolio
- 8.7.5 SIEMENS Recent Developments
- 8.8 Dongcheng
- 8.8.1 Dongcheng Comapny Information
- 8.8.2 Dongcheng Business Overview
- 8.8.3 Dongcheng Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Dongcheng Diagnostic Nuclear Medicines Product Portfolio
- 8.8.5 Dongcheng Recent Developments
- 8.9 Eli Lilly
- 8.9.1 Eli Lilly Comapny Information
- 8.9.2 Eli Lilly Business Overview
- 8.9.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Eli Lilly Diagnostic Nuclear Medicines Product Portfolio
- 8.9.5 Eli Lilly Recent Developments
- 8.10 Novartis
- 8.10.1 Novartis Comapny Information
- 8.10.2 Novartis Business Overview
- 8.10.3 Novartis Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Novartis Diagnostic Nuclear Medicines Product Portfolio
- 8.10.5 Novartis Recent Developments
- 8.11 China Isotope & Radiation
- 8.11.1 China Isotope & Radiation Comapny Information
- 8.11.2 China Isotope & Radiation Business Overview
- 8.11.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2020-2025)
- 8.11.4 China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio
- 8.11.5 China Isotope & Radiation Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Diagnostic Nuclear Medicines Value Chain Analysis
- 9.1.1 Diagnostic Nuclear Medicines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Diagnostic Nuclear Medicines Sales Mode & Process
- 9.2 Diagnostic Nuclear Medicines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Diagnostic Nuclear Medicines Distributors
- 9.2.3 Diagnostic Nuclear Medicines Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


